06|2021
IR PRESENTATION
Dr. Dirk Wössner, CEO
Michael Rauch, CFO
Claudia Thomé, CVP IR
Disclaimer
The information provided in this presentation pertaining to CompuGroup Medical SE & Co. KGaA (the "Company"), comprise the written materials/slides for presentations or discussions on the occasion of an investor conference, meeting or conference call ("Meeting"). Whilst all reasonable care has been taken to ensure that the information and facts stated herein as well as oral statements made in the Meeting are accurate and that the opinions and expectations contained herein and orally received during the Meeting are fair and reasonable, no representation or warranty, express or implied, is given by or on behalf of the Company, any of its board members, or any other person as to the accuracy or completeness of the information and/or opinions and no liability as to the accuracy of such information and/or opinions is accepted. The information provided in this presentation as well as during the Meeting contain forward looking statements which involve risks and uncertainties. These forward-looking statements speak only as of the date of the documents and are based on numerous assumptions which may or may not prove to be correct. The actual performance and results of the business of the Company could differ materially from the performance and results discussed in this document or in any other information received during the Meeting. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements or other information contained herein or received during the Meeting whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Readers are cautioned not to place undue reliance on forward-looking statements or financial projections. The information contained in this presentation and/or received during the Meeting does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation thereto.
2 | May 2021 | IR presentation |
CompuGroup Medical - A major beneficiary of digitization in healthcare
Digitization
& Interoperability
along the patient journey
while protecting
medical data and infrastructure
3 | May 2021 | IR presentation |
Servicing the entire healthcare ecosystem, we are ideally positioned for growth
REV SHARE
CUSTOMERS
MARKET POSITIONS
GROWTH
AIS - Ambulatory
Information Systems
45%
Doctors (GPs, specialists), therapists, nurses…
#1 | Germany, France, |
Austria, Czech Republic, | |
Sweden, Denmark | |
#2 | Italy, Belgium, Norway |
#3 | Slovakia, Netherlands |
#4 | USA |
HIS - Hospital | CHS - Consumer & | PCS - Pharmacy | |||||||
Information Systems | Health Management | Information Systems | |||||||
22% | 19% | 14% | |||||||
Hospitals (acute, post- | All healthcare participants, | Pharmacies | |||||||
acute), laboratories | pharma & insurance | ||||||||
companies, patients | |||||||||
#2 | D-A-CH | #1|2 | Frontrunner in | #1 | Italy | ||||
#2 | Spain (public hospitals) | Telematics | #4 | Germany | |||||
Infrastructure (TI) | |||||||||
#2 | Poland | ||||||||
Sweden | |||||||||
#1 | |||||||||
DIGITIZATION & REGULATORY INITIATIVES
DRIVERS (mid-term)
Additional modules & | TI: new user groups & | Additional modules & | ||||
Rollout of G3 platform | ||||||
functionalities | Hospital Future Act | modules | functionalities | |||
Patient portals & | (Germany) | Data services | G3 rollout | |||
telemedicine (Clickdoc) | P1 project (Poland) | Patient portals | ||||
US synergies & scale effects | ||||||
4 | May 2021 | IR presentation |
Excellent long-term financial track record
Growth | 33% | 26% | 33% | 21% | 28% | 27% | 28% | 7% | 27% | 13% | 2% | 12% | 5% | 3% | 4% | 23% | 4% | 12% | |||||||||
837 | CAGR: 17% | ||||||||||||||||||||||||||
460 | 515 | 543 | 560 | 582 | 717 | 746 | |||||||||||||||||||||
293 | 312 | 397 | 451 | ||||||||||||||||||||||||
116 | 140 | 180 | 229 | ||||||||||||||||||||||||
52 | 69 | 87 | |||||||||||||||||||||||||
Revenue in €m | |||||||||||||||||||||||||||
2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |||||||||
Margin | |||||||||||||||||||||||||||
31% | 26% | 36% | 34% | 27% | 28% | 21% | 20% | 21% | 19% | 23% | 21% | 19% | 21% | 22% | 22% | 26% | 27% | 26% | |||||||||
CAGR: 16% | |||||||||||||||||||||||||||
105 | 98 | 96 | 112 | 126 | 128 | 188 | 198 | 215 | |||||||||||||||||||
67 | 74 | ||||||||||||||||||||||||||
31 | 40 | 38 | 51 | 49 | 59 | ||||||||||||||||||||||
16 | 18 | ||||||||||||||||||||||||||
EBITDA in €m | |||||||||||||||||||||||||||
2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |||||||||
1.95 | CAGR: 17% | ||||||||||||||||||||||||||
1.74 | 1.90 | ||||||||||||||||||||||||||
0.22 | 0.33 | 0.26 | 0.46 | 0.24 | 0.33 | 0.62 | 0.48 | 0.52 | 0.77 | 0.90 | 0.63 | ||||||||||||||||
0.12 | 0.03 | 0.03 | 0.19 | ||||||||||||||||||||||||
EPS in € | |||||||||||||||||||||||||||
2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
EBITDA and eps adjusted for 2011, 2014, 2018, 2019, 2020.
5 | May 2021 | IR presentation |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
CompuGroup Medical SE published this content on 14 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2021 10:55:05 UTC.